PDS Planning Inc Has $182,000 Holdings in Akebia Therapeutics, Inc. $AKBA

PDS Planning Inc grew its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 11.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,000 shares of the biopharmaceutical company’s stock after purchasing an additional 5,000 shares during the period. PDS Planning Inc’s holdings in Akebia Therapeutics were worth $182,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Akebia Therapeutics by 16.6% during the 1st quarter. Vanguard Group Inc. now owns 12,685,803 shares of the biopharmaceutical company’s stock worth $24,357,000 after purchasing an additional 1,801,603 shares in the last quarter. AIGH Capital Management LLC bought a new stake in shares of Akebia Therapeutics during the 1st quarter worth approximately $5,616,000. Goldman Sachs Group Inc. lifted its holdings in shares of Akebia Therapeutics by 171.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company’s stock worth $5,231,000 after acquiring an additional 1,722,245 shares during the period. Woodline Partners LP bought a new stake in shares of Akebia Therapeutics during the 1st quarter worth approximately $4,772,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Akebia Therapeutics during the 1st quarter worth approximately $3,840,000. Institutional investors and hedge funds own 33.92% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AKBA. Wall Street Zen downgraded shares of Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Akebia Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Akebia Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.75.

Akebia Therapeutics Price Performance

AKBA stock opened at $2.78 on Tuesday. The company has a fifty day moving average price of $3.02 and a 200-day moving average price of $3.00. The company has a market capitalization of $737.09 million, a P/E ratio of -16.35 and a beta of 0.68. Akebia Therapeutics, Inc. has a 52-week low of $1.30 and a 52-week high of $4.08. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.84 and a current ratio of 1.98.

Akebia Therapeutics Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.